Anti-cN-1A (NT5c1A) IBM




Test Mnemonic

CN1AAB

CPT Codes

  • 83516 - QTY (1)

Aliases

  • Anti-IBM
  • IBM
  • Inclusion Body Myopathy
  • MUP44 AB
  • nt5c1a
  • sIBM
  • sporadic IBM

Includes

  • Anti-cN-1A (NT5c1A) IBM

Performing Laboratory

LabCorp


Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
2 mLSerumNo additive (Red) RefrigeratedSeparate serum from cells ASAP or within 1 hour of collection and transfer to standard aliquot tube. Additional specimens must be submitted when multiple tests are ordered.

Alternate Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
2 mLSerumSST (Gold) RefrigeratedSeparate serum from cells ASAP or within 1 hour of collection and transfer to standard aliquot tube. Additional specimens must be submitted when multiple tests are ordered.

Minimum Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
0.5 mL    Does not allow for repeat testing

Stability

Environmental Condition Description
Refrigerated14 days
Frozen60 days (1 freeze/thaw cycle)
Ambient7 days

Days Performed

Varies

Turnaround Time

8 - 11 days

Methodology

Name Description
Enzyme-Linked Immunosorbent Assay (ELISA) 

Reference Range

Anti-cN-1A (NT5c1A) IBM
Sex Age From Age To Type Range Range Unit
       Negative: <20 
       Weak Positive: 20 - 39 
       Moderate Positive: 40 - 80 
       Strong Positive: >80 

Special Info

Grossly hemolyzed, lipemic or icteric specimens will be rejected.

Clinical Info

Anti-cN-1A autoantibodies in idiopathic inflammatory myopathy (IIM) patients appear to be disease-specific for sporadic Inclusion Body Myositis (sIBM) and are rarely detected in other autoimmune conditions. Anti-cN-1A autoantibodies have a moderate sensitivity, but their high specificity for sIBM may be helpful in the diagnosis of this infrequent and difficult-to-diagnose myopathy. This assay can augment and accelerate the suspected diagnosis of sIBM using sera where muscle biopsy is delayed and/or unfeasible.